Impact of diabetes group visits on patient clinical and self-reported outcomes in community health centers

BMC Endocrine Disorders

Table 2 Changes in Clinical Outcomes by Arm over Time Compared to Baseline (Total n = 123)

	Group Visit (n = 51)
	Mean Change (95% CI)
	6-month	12-month	6-month	12-month	6-month	12-month
Glycosylated hemoglobin (A1C, %)	-1.34 (-1.88—-0.80)†	-1.26 (-1.79—-0.74)†	-0.52 (-0.97—-0.07)‡	0.26 (-0.21 -0.76)	-1.04 (-1.64—-0.44)§	-1.76 (-2.44—-1.07)†
Low density lipoprotein (LDL) (mg/dL)	-24.1 (-36.9—-11.2)†	1.1 (-11.9 -14.1)	-6.7 (-19.5 -6.2)	12.8 (-1.6 -27.1)	-14.3 (-30.4—1.9)	-8.56 (-26.1—9.0)
Systolic blood pressure (mmHg)	-0.73 (-6.13 -4.66)	0.84 (-4.52 -6.19)	1.63 (-2.95 -6.22)	-2.00 (-6.77 -2.77)	-3.56(-10.33—3.20)	1.64 (-5.60—8.88)
Weight (lbs)	1.52 (-2.55 -5.59)	1.26 (-2.76 -5.29)	-3.20 (-6.35—-0.06)‡	-7.01 (-10.17—-3.85)†	3.97 (-1.48 -9.43)	7.52 (1.74 -13.29)†

Adjusted mean difference is from a linear mixed model that adjusts for the random effects of clinics, and repeated effects of the clinical measure over time patient. In addition, each model adjusts for the effects of study group, time, baseline clinical value, interactions group x time and baseline value x time, duration of diabetes and type of insurance. All participants with baseline and at least one follow-up measure were included to make the model robust
^*Intervention effect was calculated by subtracting the control arm estimate from the intervention arm estimate
^† p < 0.001;
^‡ p < 0.05;
^§ p < 0.01

ISSN: 1472-6823